<bill session="116" type="h" number="6930" updated="2023-01-11T13:42:52Z">
  <state datetime="2020-05-19">REFERRED</state>
  <status>
    <introduced datetime="2020-05-19"/>
  </status>
  <introduced datetime="2020-05-19"/>
  <titles>
    <title type="display">MADE in America Act of 2020</title>
    <title type="official" as="introduced">To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes.</title>
    <title type="short" as="introduced">MADE in America Act of 2020</title>
    <title type="short" as="introduced">Manufacturing API, Drugs, and Excipients in America Act of 2020</title>
  </titles>
  <sponsor bioguide_id="C001103"/>
  <cosponsors>
    <cosponsor bioguide_id="C001090" joined="2020-07-09"/>
    <cosponsor bioguide_id="C001087" joined="2020-05-19"/>
    <cosponsor bioguide_id="G000568" joined="2020-05-19"/>
    <cosponsor bioguide_id="M001180" joined="2020-05-19"/>
    <cosponsor bioguide_id="R000597" joined="2020-10-01"/>
    <cosponsor bioguide_id="S001200" joined="2020-05-19"/>
    <cosponsor bioguide_id="V000133" joined="2020-06-18"/>
    <cosponsor bioguide_id="W000821" joined="2020-06-18"/>
  </cosponsors>
  <actions>
    <action datetime="2020-05-19">
      <text>Introduced in House</text>
    </action>
    <action datetime="2020-05-19" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2020-05-19">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Referral"/>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Advanced technology and technological innovations"/>
    <term name="Buy American requirements"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Foreign and international corporations"/>
    <term name="Government information and archives"/>
    <term name="Government studies and investigations"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Income tax credits"/>
    <term name="Income tax deductions"/>
    <term name="Manufacturing"/>
    <term name="Prescription drugs"/>
    <term name="Taxation of foreign income"/>
    <term name="Technology assessment"/>
    <term name="Wages and earnings"/>
  </subjects>
  <amendments/>
  <summary date="2021-01-28T15:19:36Z" status="Introduced in House">Manufacturing API, Drugs, and Excipients in America Act of 2020 or the MADE in America Act of 2020

This bill establishes a tax credit for taxpayers engaged in medical production activities in certain areas and contains other provisions related to pharmaceuticals.

An eligible taxpayer may claim a tax credit equal to 30% of qualified expenditures related to the production of pharmaceuticals, medical devices, or other related items in a designated qualified opportunity zone with a poverty rate higher than 30%.

In addition, the Food and Drug Administration shall continue a program to evaluate new drug manufacturing technologies included in an application for approval of a drug or biological product. The bill imposes various requirements on this program, including deadlines for evaluating such a technology.

Furthermore, the Department of Health and Human Services shall establish or expand programs to promote regulatory consistency and cooperation with drug regulatory authorities in other countries.</summary>
</bill>
